
Tony Duckworth to lead Albany-area YMCA
ALBANY — When Tony Duckworth stepped away from his role as Albany State University's athletic director in 2023, he didn't expect his next opportunity to come from one of Albany's most community-centered institutions: the YMCA.
In June, Duckworth will officially take over as director of the Albany-area YMCA, following the retirement of longtime leader Dan Gillan.
'I wanted to stay in Albany,' Duckworth said. 'That was the deciding factor.'
After leaving Albany State, Duckworth turned down several out-of-town opportunities before accepting a position with Syneos Health, a pharmaceutical company. But even as he settled into that role, he kept an eye out for meaningful leadership opportunities in the Albany area.
Off the clock, he remained a familiar face in the community, officiating high school basketball and baseball games and writing a popular weekly column for The Albany Herald.
The Path to the YMCA
It was a connection from his time on the NCAA Division II basketball selection committee that first introduced Duckworth to the idea of YMCA leadership. A fellow athletic director on the committee had taken a CEO role at a Pennsylvania YMCA shortly after Duckworth left ASU.
'That was the first time I really considered nonprofit leadership,' Duckworth said. 'It stayed in the back of my mind.'
When Gillan announced his plans to retire, a local Albany State booster let Duckworth know about the opening. He applied, and after what he called an 'exhaustive' interview process, he was selected to lead the organization.
Similar Roles, New Mission
Transitioning from collegiate athletics to a nonprofit organization may seem like a shift, but Duckworth sees plenty of overlap.
'There are a lot of parallels,' he said. 'As a Division II athletic director, you wear many hats—staffing, budgeting, resolving complaints, running events, sweeping floors, driving buses, and fundraising. That's very similar to nonprofit leadership.'
At the YMCA, Duckworth is especially motivated by programs that serve youth and families in need.
'We're feeding kids who might not get another meal that day,' he said. 'Feeding the Valley provides those meals, and both our afterschool programs and our partners at Easter Seals benefit from that relationship. It's a mission-driven operation that calls for creativity and compassion.'
Listening First, Then Leading
Rather than implementing immediate changes, Duckworth said his first few months on the job will be focused on understanding the organization's people and culture.
'For the first three to six months, I'm going to be listening,' he said. 'I want to understand the day-to-day operations, the roles of our team, and the needs of our members. If I'm asking questions, it's not to challenge—it's to learn.'
Growth and Facility Improvements
Though large-scale changes aren't imminent, Duckworth said improvements are already underway thanks to federal funding secured by Gillan through U.S. Senator Jon Ossoff.
'Members at the Gillionville Road facility will see aesthetic upgrades around the indoor pool and behind-the-scenes work that's just as important,' Duckworth said. 'A new HVAC system is also going into the gym.'
Looking further ahead, he's excited about potential expansion, especially at the Lee County YMCA.
'There's a lot of development happening in that area,' he said. 'Our board is forward-thinking, and I hope to be a strong voice as we plan for future growth.'
For Duckworth, leading the YMCA feels like a natural extension of his passion for serving people.
'The Y is truly a one-stop shop,' he said. 'It's the only place in town that serves everyone—from elementary school kids to senior citizens. No one else does what the YMCA does, and I'm honored to help continue that mission.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
CancerVax Targets Liver Cancers to Further Showcase Flexibility of Its Universal Platform
Using AI machine learning, the Company discovers distinct biomarkers for detecting certain rare liver cancers that have stem cell characteristics and will include them as additional indications in its preclinical program Lehi, Utah, June 09, 2025 (GLOBE NEWSWIRE) -- CancerVax, Inc., the developer of a breakthrough universal cancer treatment platform designed to use the body's immune system to treat cancer, today announced that it will expand its preclinical program to include liver cancers, specifically rare stem cell-like forms of hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). Patients with these stem cell-like tumors have a significantly worse survival than patients with more traditional liver tumors. CancerVax's novel platform uses engineered lipid nanoparticles to detect and mark only cancer cells for destruction by the immune system. The nanoparticles use a 2-step detection mechanism to precisely target cancer cells, while leaving healthy cells unharmed. The nanoparticles first target cells with specific surface proteins ('Marker1'), then release proprietary Smart mRNAs that are activated only in the presence of cancer-specific signatures ('Marker2'). Once activated, the mRNA forces cancer cells to express proteins associated with well-immunized diseases like measles, effectively tricking the immune system into killing cancer cells as if they were common diseases. The Company previously announced that it was targeting pancreatic ductal adenocarcinoma (PDAC) in its preclinical program. After extensive research and AI-driven analysis, the Company's scientific team has discovered a very distinct Marker2 signature for a group of rare liver cancers. These tumors have stem cell characteristics, making them more aggressive and less responsive to traditional therapies. By taking advantage of the distinct Marker2 signature, CancerVax believes it can overcome the severe unmet clinical need for these cancer patients and can more quickly validate the universality of its platform. The Company's preclinical cancer indications will now be expanded to three (3) cancer types: PDAC, rare HCC and ICC. Dr. Adam Grant, Principal Scientist of CancerVax said, "When we first identified these subsets of liver cancers with this distinct Marker2 signature, I couldn't believe it. It was amazing to come across a patient population that has a high unmet clinical need and is uniquely suited to validate our technology. Of course, we expect that our platform will work on many different cancer types but the unique genetic signatures in these rare liver cancers make them a no-brainer for us to target. This precision-based discovery is what every computational biologist dreams of and I'm beyond excited to have the opportunity to help provide relief for these patients with severely poor outcomes. Dr. George Katibah, Chief Scientific Officer of CancerVax said, "The results from our AI data analytics are really striking. This particular cancer biology leads to not one but a group of rare liver cancers for which there are limited treatments. Our team has uncovered this novel cancer stem cell biology using advanced computational techniques showing that these tumors' underlying biology can be targeted by the CancerVax approach. These results demonstrate the flexibility of our platform and how we can swap out Marker1 and Marker2 to attack other cancers with a precision medicine approach. The next steps include creating new nanoparticles for these new cancer indications and to perform in vitro and in vivo studies to evaluate efficacy and safety.' The Company's universal cancer treatment platform is architected in such a way that off-the-shelf injections can be created by changing the Marker1 and Marker2 combination to target different cancer types. This approach allows for the Company's immunotherapies to be broadly available when a patient is diagnosed and needs to be treated immediately. These injections are more like 'off-the-shelf' flu shots, rather than complex treatment procedures. About CancerVax CancerVax is a pre-clinical biotech company developing a novel Universal Cancer Treatment platform that will be customizable, as an injection, to treat many types of cancer. Our innovative approach DETECTS, MARKS, and KILLS only cancer cells. By making cancer cells look like well-immunized common diseases such as measles or chickenpox, we intend to use the body's natural immune system to easily kill the cancer cells. We look forward to the day when treating cancer will be as simple as getting a shot -- a better way to fight cancer. To learn more, please visit Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations, and assumptions regarding the future of our business, plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict, many of which are outside our control. Our actual results and financial condition may differ materially from those in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Any forward-looking statement made by us in this release is based only on information currently available to us and speaks only as of the date it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments, or otherwise. Press Contact:CancerVax, (805) 356-1810Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
USS Comstock returns to San Diego after 3-month mission in Indo-Pacific
SAN DIEGO (FOX 5/KUSI) — The USS Comstock returned to its homeport in San Diego on Thursday after a three month mission in the Indo-Pacific, the U.S. Navy reports. Marines and sailors aboard the Whidbey Island-class dock landing ship USS Comstock (LSD 45) returned to Naval Base San Diego on Thursday after a three-month mission to the U.S. 7th Fleet area of operations in the Indo-Pacific. The Navy says 115 U.S. Marines and Sailors from Alpha Company, 1st Light Armored Reconnaissance Battalion, 1st Marine Division also embarked Comstock during the deployment. While in U.S. 7th Fleet, the Navy says the Comstock participated in exercises Tiger Triumph in India and Balikatan 25 in the Philippines. 'Our ship's successful completion of Tiger Triumph and Balikatan 2025 is a testament to the dedication, resilience, and skill of our crew,' said Cmdr. Byron Stocks, the commanding officer of the Comstock. 'Together, we strengthened partnerships, honed our readiness, and proudly represented our nation on the world stage.' The Tiger Triumph featured 3,000 personnel, two warships, and seven aircraft, the Navy reports. The Comstock, with embarked U.S. Marines, worked alongside Indian counterparts for two weeks during the exercise. The Navy says the Tiger Triumph gave participating forces the opportunity to refine humanitarian assistance and disaster response operations, conduct amphibious beach landings and build relationships and camaraderie through cultural exchanges. 'The tireless work ethic of the U.S. and Indian Armed Forces at all levels directly contributed to the successful execution of the amphibious landing,' said U.S. Marine Capt. Erik Ayala, commander of troops for Alpha Company, 1st Light Armored Reconnaissance Battalion, 1st Marine Division. 'This success highlights the cohesion we currently have with our Indian Partners and will enable us to build on the complexity in the future.' After completing the Tiger Triumph exercise, the Comstock participated in exercise Balikatan 25 from April 25-29 alongside the Philippine Navy and the Japan Maritime Defense Force, according to the Navy. In addition to humanitarian projects and logistics operations, the Navy says the exercise featured a Full Battle Test, which combines all domains — air, land, sea, space and cyber, while the group sail tested maritime maneuvers and validated interoperability of doctrine, tactics, techniques, and procedures at sea. The USS Comstock (LSD 45) is a Whidbey Island-class dock landing ship homeported in San Diego. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
an hour ago
- Yahoo
Skydiving plane crashes in Tennessee with 20 people on board
The Brief Several people were injured after a skydiving plane crashed in Tennessee. Officials didn't say where the plane was headed or what caused the crash. A skydiving plane carrying 20 people crashed soon after taking off in Tennessee Sunday, authorities said. According to the Tennessee Highway Patrol, six people were injured, but officials said there were no casualties. What we know The crash happened Sunday afternoon in Tullahoma, Tennessee. RELATED: Deadly U.S. plane crashes in 2025: Timeline Officials said there were 20 people on board, including crew members, when the skydiving plane crashed shortly after takeoff. Police said six people were injured and flown to area hospitals. RELATED: U.S. issues 'do not travel' warning for 21 countries. What to know Video shared by Tennessee Highway Patrol shows the crash site with several plane parts scattered across a field. What we don't know It's unclear where the passengers were set to skydive or what caused the plane crash. The extent of the injuries is also unknown, but officials told People they appeared to be minor. What's next The Federal Aviation Administration will investigate the cause. The Source This report includes information from Tennessee Highway Patrol and People.